Comparison · NCT01067469-deaths
Standard Dose Bevacizumab vs Low Dose Bevacizumab + Lomustine: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Standard Dose Bevacizumab vs Low Dose Bevacizumab + Lomustine: deaths from any cause. Trial comparisons, record NCT01067469-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01067469-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.167 | 0.0787 | 0.319 | wilson | |
| Risk in group 2 | 0.0303 | 0.00537 | 0.153 | wilson | |
| Risk difference, group 1 minus group 2 | 0.136 | -0.0148 | 0.291 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 5.5 | 0.698 | 43.3 | log | |
| Odds ratio, group 1 over group 2 | 6.4 | 0.727 | 56.3 | log | |
| Number needed to harm, for one more death from any cause on Standard Dose Bevacizumab than on Low Dose Bevacizumab + Lomustine | 7.33 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Standard Dose Bevacizumab | Bevacizumab 10 mg/kg by vein (IV) over 90 minutes on Days 1, 15, and 29 of 6 week cycle. | 6 | 36 | EG000 |
| Group 2 | Low Dose Bevacizumab + Lomustine | Bevacizumab 5 mg/kg IV over 90 minutes on Day 1 and 22 (every 3 weeks) of 6 week cycle. Lomustine starting dose of 90 mg/m2 administered orally at sleep time on Day 3 of every 6 week cycle. Due to hematologic toxicities, the starting dose was reduced to 75 mg/m2. | 1 | 33 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- Adverse event data collected every six weeks after baseline, up to one year (52 weeks).
Source ClinicalTrials.gov
Trial
- Title
- Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)
- NCT number
- NCT01067469
- Phases
- PHASE2
- Conditions
- Brain Cancer, Glioblastoma
- Interventions
- Standard Dose Bevacizumab, Low Dose Bevacizumab, Lomustine
- Lead sponsor
- M.D. Anderson Cancer Center
- Results first posted
- 2020-03-17
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01067469?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01067469-deaths